Virpax Pharmaceuticals Inc - ESG Rating & Company Profile powered by AI
The Disclosure rating includes 17 UN SDGs including: 'Clean Water & Sanitation', 'Reduced Inequalities' and 'Peace, Justice & Strong Institutions'. This webpage displays a zero-cost Sustainability analysis covering Virpax Pharmaceuticals Inc. Browse to the bottom of this webpage for potential risks for Virpax Pharmaceuticals Inc based on sector, geography and size.
Virpax Pharmaceuticals Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 6.7; made up of an environmental score of 4.0, social score of 8.0 and governance score of 8.0.
6.7
Medium ImpactEnvironmental
Social
Governance

Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Caladrius Biosciences Inc | 8.0 | High |
1 | Can Fite Biopharma Ltd | 8.0 | High |
314 | Trulieve Cannabis Corp | 6.8 | High |
314 | Vicore Pharma Holding AB | 6.8 | High |
337 | Virpax Pharmaceuticals Inc | 6.7 | High |
337 | Calyxt Inc | 6.7 | High |
337 | CanSino Biologics Inc | 6.7 | High |
... | ... | ... | |
1970 | Zyden Gentec Ltd | 0.0 | Low |
1970 | iNtRON Biotechnology Inc | 0.0 | Low |
... | ... | ... |

Frequently Asked Questions
Does Virpax Pharmaceuticals Inc have an accelerator or VC vehicle to help deliver innovation?
Does Virpax Pharmaceuticals Inc disclose current and historical energy intensity?
Does Virpax Pharmaceuticals Inc report the average age of the workforce?
Does Virpax Pharmaceuticals Inc reference operational or capital allocation in relation to climate change?
Does Virpax Pharmaceuticals Inc disclose its ethnicity pay gap?
Does Virpax Pharmaceuticals Inc disclose cybersecurity risks?
Does Virpax Pharmaceuticals Inc offer flexible work?
Does Virpax Pharmaceuticals Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does Virpax Pharmaceuticals Inc disclose the number of employees in R&D functions?
Does Virpax Pharmaceuticals Inc conduct supply chain audits?
Does Virpax Pharmaceuticals Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does Virpax Pharmaceuticals Inc conduct 360 degree staff reviews?
Does Virpax Pharmaceuticals Inc disclose the individual responsible for D&I?
Does Virpax Pharmaceuticals Inc disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does Virpax Pharmaceuticals Inc disclose current and / or historical scope 2 emissions?
Does Virpax Pharmaceuticals Inc disclose water use targets?
Does Virpax Pharmaceuticals Inc have careers partnerships with academic institutions?
Did Virpax Pharmaceuticals Inc have a product recall in the last two years?
Does Virpax Pharmaceuticals Inc disclose incidents of discrimination?
Does Virpax Pharmaceuticals Inc allow for Work Councils/Collective Agreements to be formed?
Has Virpax Pharmaceuticals Inc issued a profit warning in the past 24 months?
Does Virpax Pharmaceuticals Inc disclose parental leave metrics?
Does Virpax Pharmaceuticals Inc disclose climate scenario or pathway analysis?
Does Virpax Pharmaceuticals Inc disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does Virpax Pharmaceuticals Inc disclose the pay ratio of women to men?
Does Virpax Pharmaceuticals Inc support suppliers with sustainability related research and development?
Does Virpax Pharmaceuticals Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does Virpax Pharmaceuticals Inc reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is Virpax Pharmaceuticals Inc involved in embryonic stem cell research?
Does Virpax Pharmaceuticals Inc disclose GHG and Air Emissions intensity?
Does Virpax Pharmaceuticals Inc disclose its waste policy?
Does Virpax Pharmaceuticals Inc report according to TCFD requirements?
Does Virpax Pharmaceuticals Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does Virpax Pharmaceuticals Inc disclose energy use targets?
Does Virpax Pharmaceuticals Inc disclose its Renewable Energy targets?

Are emissions metrics verified by STBi?

Does Virpax Pharmaceuticals Inc have a policy relating to cyber security?
Have a different question?
Potential Risks for Virpax Pharmaceuticals Inc
These potential risks are based on the size, segment and geographies of the company.
Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical nonsteroidal anti-inflammatory drug treatment for chronic osteoarthritis of the knee; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain. The company's preclinical stage product candidates also comprise PES200, which enables the delivery of a metabolically labile peptide drug into the brain; AnQlar, an anti-viral barrier to prevent or reduce the risk or the intensity of viral infections in humans, including influenza and SARS-CoV-2; and VRP324, an investigational formulation to be delivered via the nasal route to enhance cannabidiol transport to the brain. Virpax Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Berwyn, Pennsylvania.